Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25171645 | 0.78 | BTK (0.53) | BTK | |
| SCHEMBL25456300 | 0.74 | EGFR (0.54) | BTK | |
| SCHEMBL25456317 | 0.74 | EGFR (0.50) | BTK | |
| SCHEMBL23815874 | 0.72 | EGFR (0.69) | BTK | |
| SCHEMBL25171837 | 0.72 | JAK2 (0.39) | BTK | |
| SCHEMBL20533284 | 0.71 | EGFR (0.52) | BTK | |
| SCHEMBL20994920 | 0.70 | BTK (1.00) | BTK | |
| SCHEMBL20994921 | 0.70 | BTK (1.00) | BTK | |
| SCHEMBL20994958 | 0.70 | BTK (1.00) | BTK | |
| SCHEMBL20995040 | 0.69 | BTK (0.90) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4118086-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Fochon Biosciences, Ltd. (CN) | 2023-01-18 | — | — | EP | disclosed |
| CN-115443277-A | Compounds as kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2022-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.